Meeting News

Ado-trastuzumab emtansine offers effective, tolerable option for breast cancer subtype

August 22, 2018
CHICAGO – Safety outcomes with first-line ado-trastuzumab emtansine in the final descriptive analysis of the MARIANNE trial appear similar to…
Meeting News

Guest Commentary: Targeted therapies appear effective in breast cancer subtypes

August 22, 2018
In this guest commentary, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD
Meeting News

Chemotherapy-free regimen in Ki67 responders ‘warrants further investigation’

July 20, 2018
De-escalated treatment with trastuzumab, pertuzumab and letrozole an effective, chemotherapy-free regimen for patients with hormone…
Meeting NewsPerspective

Everolimus plus exemestane improves PFS, appears safe in advanced breast cancer

July 19, 2018
Everolimus plus exemestane resulted in a greater PFS benefit versus everolimus alone in patients with estrogen receptor-positive, HER-2-negative…
Meeting NewsPerspective

Sacituzumab govitecan appears safe, effective in heavily pretreated breast cancer subtype

July 18, 2018
Treatment with sacituzumab govitecan, a novel antibody-drug conjugate, resulted in objective responses among women with heavily pretreated hormone…
Meeting News

Denosumab improves DFS, bone-related outcomes in breast cancer subtype

June 25, 2018
Adjuvant denosumab may improve DFS and bone-related outcomes among postmenopausal women with early-stage, hormone receptor-positive breast cancer…